Peripheral T-Cell Lymphoma, Not Otherwise Specified · line 2 · Pralatrexate 30 mg/m² IV weekly × 6 of 7-week cycle (PROPEL schedule) — r/r PTCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-PRALATREXATE-PTCL |
| ID | IND-PTCL-2L-PRALATREXATE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PTCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L+ for r/r PTCL NOS. UA access barrier dominant — international supply required. Bridge to alloSCT consolidation standard in fit responders.
Used By
Algorithms
ALGO-PTCL-2L- ALGO-PTCL-2L